|Podcasts|July 16, 2013
What does RBM mean to Sanofi's CRAs and site monitors
Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?
Advertisement
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE SummitFebruary 7th 2025
The MDR: Navigating Europe’s New Standard for Medical Device SafetyOctober 25th 2022
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
3
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
